- Home
- KYMR vs TMDX Comparison
KYMR vs TMDX Comparison
Compare KYMR & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYMR
- TMDX
- Stock Information
- Founded
- KYMR 2015
- TMDX 1998
- Country
- KYMR United States
- TMDX United States
- Employees
- KYMR N/A
- TMDX N/A
- Industry
- KYMR Medicinal Chemicals and Botanical Products
- TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- KYMR Health Care
- TMDX Health Care
- Exchange
- KYMR Nasdaq
- TMDX Nasdaq
- Market Cap
- KYMR 2.1B
- TMDX 2.3B
- IPO Year
- KYMR 2020
- TMDX 2019
- Fundamental
- Price
- KYMR $33.45
- TMDX $64.35
- Analyst Decision
- KYMR Buy
- TMDX Buy
- Analyst Count
- KYMR 13
- TMDX 10
- Target Price
- KYMR $56.69
- TMDX $118.44
- AVG Volume (30 Days)
- KYMR 695.8K
- TMDX 1.4M
- Earning Date
- KYMR 05-01-2025
- TMDX 04-29-2025
- Dividend Yield
- KYMR N/A
- TMDX N/A
- EPS Growth
- KYMR N/A
- TMDX N/A
- EPS
- KYMR N/A
- TMDX 1.01
- Revenue
- KYMR $47,072,000.00
- TMDX $441,540,000.00
- Revenue This Year
- KYMR $44.93
- TMDX $25.24
- Revenue Next Year
- KYMR N/A
- TMDX $19.89
- P/E Ratio
- KYMR N/A
- TMDX $63.70
- Revenue Growth
- KYMR N/A
- TMDX 82.74
- 52 Week Low
- KYMR $29.07
- TMDX $55.00
- 52 Week High
- KYMR $53.27
- TMDX $177.37
- Technical
- Relative Strength Index (RSI)
- KYMR 44.68
- TMDX 41.92
- Support Level
- KYMR $31.54
- TMDX $62.07
- Resistance Level
- KYMR $31.66
- TMDX $69.67
- Average True Range (ATR)
- KYMR 2.31
- TMDX 5.02
- MACD
- KYMR 0.37
- TMDX -0.94
- Stochastic Oscillator
- KYMR 51.20
- TMDX 12.55
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
About TMDX TransMedics Group Inc.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.